These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The combination measles, mumps, rubella and varicella vaccine in healthy children. Arbeter AM; Baker L; Starr SE; Plotkin SA Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864 [TBL] [Abstract][Full Text] [Related]
3. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ; Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Goh P; Lim FS; Han HH; Willems P Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
8. Combined vaccine against measles, mumps, rubella, and varicella. Brunell PA; Novelli VM; Lipton SV; Pollock B Pediatrics; 1988 Jun; 81(6):779-84. PubMed ID: 2835743 [TBL] [Abstract][Full Text] [Related]
9. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Dennehy PH; Saracen CL; Peter G Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862 [TBL] [Abstract][Full Text] [Related]
10. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Nolan T; McIntyre P; Roberton D; Descamps D Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. Leung JH; Hirai HW; Tsoi KK Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133 [TBL] [Abstract][Full Text] [Related]
13. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Marin M; Broder KR; Temte JL; Snider DE; Seward JF; MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530 [TBL] [Abstract][Full Text] [Related]
14. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine. Shinefield HR; Black S; Kuter BJ J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. Reuman PD; Sawyer MH; Kuter BJ; Matthews H Pediatr Infect Dis J; 1997 Jul; 16(7):662-7. PubMed ID: 9239770 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants. Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218 [TBL] [Abstract][Full Text] [Related]
17. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context. Casabona G; Berton O; Singh T; Knuf M; Bonanni P Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012 [TBL] [Abstract][Full Text] [Related]
18. [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine]. Takayama N; Kidokoro M; Suzuki K; Morita M Kansenshogaku Zasshi; 1992 Jun; 66(6):776-80. PubMed ID: 1331262 [TBL] [Abstract][Full Text] [Related]
19. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety. Ma SJ; Li X; Xiong YQ; Yao AL; Chen Q Medicine (Baltimore); 2015 Nov; 94(44):e1721. PubMed ID: 26554769 [TBL] [Abstract][Full Text] [Related]
20. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ; Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]